Dallas – A new clinical trial at UT Southwestern Medical Center is giving hope to women diagnosed with early‑stage, hormone‑positive breast cancer. Led by radiation oncologist Dr. Asal Rahimi, the Phase II study tests a novel approach that delivers one high‑dose, pinpointed radiation treatment, then postpones surgery for up to a year.
Promising early results
According to findings published in JAMA Network Open in November 2025, the regimen produced remarkable outcomes. In 72% of the women treated, the tumors vanished entirely. An additional 21% saw more than 90% of the cancer eliminated. Dr. Rahimi described the results as “phenomenal,” noting that the approach could expand treatment options for many patients.
Patient story: Miss Rodeo America inductee
One participant, Pam Minick, a resident of Argyle and 2026 Miss Rodeo America Hall of Fame inductee, shared her experience. Diagnosed in July 2025, Minick received the single radiation dose and, months later, reported feeling great. She later underwent a lumpectomy to remove a small rim of healthy tissue for confirmation. Pathology showed no cancer in the biopsy, prompting her to celebrate the success during Breast Cancer Awareness Month.
How the trial works
The study, called RAPS (Radiation‑Assisted Precision Surgery), is funded by a grant from the Cancer Prevention and Research Institute of Texas (CPRIT). Participants receive a single, high‑dose radiation treatment targeted to the tumor site. The precision technology limits exposure to surrounding healthy tissue, aiming to shrink or eradicate the tumor before surgery.
After the radiation, patients are monitored with imaging. If the tumor is no longer visible, surgery can be delayed or, in some cases, may be avoided altogether. The trial’s design reflects a growing emphasis on less invasive, patient‑centered cancer care.
Call for participants
The research team is actively recruiting eligible women in the Dallas‑Fort Worth area. Interested patients can learn more by calling the study line at 833‑722‑6237. Participation offers access to cutting‑edge treatment while contributing to data that could reshape standard breast‑cancer protocols.
Community impact
Beyond the potential medical benefits, the trial underscores Dallas’s role as a hub for innovative health research. By attracting federal and state funding, UT Southwestern demonstrates how local institutions can lead national advances in cancer therapy, aligning with the community’s commitment to health, family well‑being, and scientific progress.
Original reporting: Richardson, TX News (HLL/CB) — read the source article.
